BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 23, 2026
Home » Topics » Medical technology, Deals and M&A

Medical technology, Deals and M&A
Medical technology, Deals and M&A RSS Feed RSS

Cansino partners with Aerogen for inhalable COVID vaccine

Dec. 9, 2021
By Gina Lee
Cansino Biologics Inc. has entered a development and commercial supply partnership with Aerogen Ltd. for an inhalable version of its COVID-19 vaccine, Convidecia, also known as Ad5-nCoV. Cansino will combine Convidecia with Aerogen’s vibrating mesh aerosol drug delivery technology to produce a consistent droplet size for optimal lung deposition. The technology delivers up to six times more medication to the lungs compared to jet nebulizers. It also enables consistency and drug denaturing to improve efficacy. Cansino and Aerogen did not disclose the deal’s commercial terms.
Read More
Brain waves

Nextsense emerges from stealth with biosensing earbuds

Dec. 6, 2021
By Annette Boyle
Nextsense Inc. reported partnerships with global biopharma company UCB SA, Heraus Holding GmbH, the University of California San Diego and Emory University at its first public appearance at the American Epilepsy Society Annual Meeting in Chicago this past weekend. The Nextsense platform uses biosensing earbuds to perform ongoing electroencephalograms (EEGs).
Read More
Photo of Harrison.ai co-founders with CEO

AI company Harrison.ai raises AU$129M in one of Australia’s largest series B rounds

Dec. 3, 2021
By Tamra Sami
PERTH, Australia – Health care artificial intelligence (AI) company Harrison.ai has raised AU$129 million (US$97 million) in a series B round that will expand the company’s global footprint by commercializing its comprehensive clinical AI applications.
Read More
Doctor performing surgery

Peters Surgical set to exit Eurazeo portfolio

Dec. 2, 2021
By Bernard Banga
PARIS – Peters Surgical SAS is being sold off. Its majority shareholder, Eurazeo Small-mid buyout, the investment arm for small and medium-sized enterprises at Eurazeo SE, has been preparing Peters Surgical for sale for the last five months. Investment banks DC Advisory and Allinvest are currently engaged in the sale of the company. This round is part of a divestment program at Eurazeo. Interestingly, disposals finalized since the beginning of the year have tripled, reaching $3.5 billion. The Eurazeo group, with a market cap of $6.65 billion on the Euronext Paris stock exchange, is pursuing its ambitious asset disposal program in a buoyant environment.
Read More
Gold wireframe handshake

GE Healthcare signs AI-focused cancer technology collaborations

Nov. 30, 2021
By Catherine Longworth
GE Healthcare Ltd. is expanding its cancer technology capabilities through new alliances with artificial intelligence (AI) companies and researchers. The company said it is teaming up with U.K.-based Optellum Ltd. to advance lung cancer diagnostics, as well as collaborating with the University of Cambridge to develop an AI application that integrates cancer patient data from multiple sources into a single interface.
Read More
Nurse moving Swoop off hospital elevator

Hyperfine Swoop(s) up FDA clearance for portable MRI, double-SPAC deal moves forward

Nov. 29, 2021
By Annette Boyle
The FDA cleared Hyperfine Research Inc.’s advanced image reconstruction technology using deep learning for its portable magnetic resonance imaging device, Swoop. The bedside MRI unit’s artificial intelligence application received clearance in January and is used with deep learning to improve image quality and diagnostic value. Hyperfine and Liminal Sciences Inc., which share a founder in serial entrepreneur Jonathan Rothberg, are both combining with special purpose acquisition company Healthcor Catalio Acquisition Corp. to go public in a deal valued at $580 million. The companies reported on Nov. 29 that the Securities and Exchange Commission declared the registration statement on form S-4 for the combination to be effective and the SPAC’s shareholders will vote on the transaction on Dec. 21.
Read More
Business people with hands atop a digital globe

Planet Innovation expands global footprint with U.S. acquisition of BIT Analytical Instruments

Nov. 24, 2021
By Tamra Sami
PERTH, Australia – Australian health technology company Planet Innovation is expanding its footprint into the U.S. with the acquisition of the North American operations of Germany’s medical device manufacturer BIT Analytical Instruments GmbH.
Read More
Concept of business partnership

Trajan acquires Axel Semrau lab automation and chromatography business for $18.7M

Nov. 24, 2021
By Tamra Sami
PERTH, Australia – Medical device and analytics company Trajan Group Holdings Ltd. has acquired the business and manufacturing facilities of Axel Semrau GmbH & Co., based in Sprockhövel, Germany, for AU$26 million (US$18.7 million), expanding the company’s global operations. Axel Semrau develops and manufactures laboratory automation and chromatography software and detection systems. The acquisition is the company’s most significant to date and broadens the company’s manufacturing base in Europe, Trajan founder and CEO Stephen Tomisich told BioWorld.
Read More
Stratasys 3D printers deployed at Hôpital Cochin

Bone 3D, Stratasys partner to deploy 3D printing across French hospitals

Nov. 16, 2021
By Bernard Banga
PARIS – Bone 3D SAS has signed a partnership with Stratasys Ltd. to put 3D printing technology directly into the hands of all 3,000 French hospitals and their front-line medical professionals. This new service, called Hospifactory, makes it possible to leverage additive manufacturing to produce medical equipment and devices directly on site at the hospital.
Read More
Health professional holding stethoscope with health icons

Jefferies report: Investor appetite for health care is strong

Nov. 16, 2021
By Catherine Longworth
A research report by global investment bank Jefferies has found increased investor optimism in the health care market amid COVID-19, with respondents expecting stocks to rise throughout 2022. The Jefferies Healthcare Temperature Check summarizes the views of 500 leaders across the health care sector. Sixty percent of respondents said they believed the MSCI World Health Care Index would be higher by the end of 2022 than at present.
Read More
Previous 1 2 … 45 46 47 48 49 50 51 52 53 … 79 80 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 22, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • Click chemistry drug bound to pancreatic cancer cells from mice

    In vivo click ADCs could address tumor heterogeneity

    BioWorld
    Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...
  • Tree in the shape of human head losing leaves

    KBN-2201 reverses key features of Alzheimer’s in mice

    BioWorld Science
    Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing